Go back

Annie Lamont – A Lifetime in Venture, Venture is Eating the Investment World 9 (Capital Allocators, EP. 238)

from Capital Allocators – Inside the Institutional Investment Industry

52m 42s

Annie Lamont – A Lifetime in Venture, Venture is Eating the Investment World 9 (Capital Allocators, EP. 238)

Annie Lamont, co-founder of Oak HCFT, shares her 40-year journey in venture capital, starting in the early 1980s with a focus on biotech before pivoting to healthcare and fintech post-2000 market crash. She emphasizes that the most critical factor in her investment decisions is the quality of the CEO—someone who is confident, intellectually curious, and capable of building superior teams. Her process combines deep industry relationships, rigorous due diligence, and a focus on operational excellence, including dedicated talent teams to support portfolio companies. She highlights transformative trends in healthcare, such as pay-viders and home-based virtual care, and fintech innovations like blockchain infrastructure via Paxos. Lamont also reflects on the evolving VC landscape, noting increased competition, the importance of brand and market share, and the need for disciplined fund sizing. She attributes success to a strong network effect and ongoing learning, while advocating for greater gender inclusion in the industry. Her experience as Connecticut’s first lady further underscores her commitment to public policy and entrepreneurial ecosystems. The episode positions venture capital as a dynamic, people-driven field shaped by innovation, adaptability, and long-term vision. Platforms like AlphaSense, Ridgeline, and Juniper Square are highlighted as tools that support capital allocators in research, operations, and data management.

Transcription

9160 Words, 51500 Characters

English
Capital allocators is brought to you by AlphaSense. Every allocator sits at their desk for hours preparing the work around investment decisions, getting up to speed on a new theme, prepping for the next investment committee meeting, and tracking with changes across an entire portfolio. AlphaSense just launched something built to help. It's called "super analyst" and always on agent that works like a power user on your behalf. It draws on over 500 million premium sources, including broker research, expert transcripts, company filings, and earnings calls, and keeps working long after you've gone home for the day. Point super analyst at a theme, company, or market, and it learns the coverage universe so you can easily turn new insights into the briefs, models, and memos, you'd otherwise build by hand. It was designed to work like an extension of your team, so it remembers your projects, follows your template to processes, and links every output to its source so you can see where each conclusion came from. The best way to judge its quality is to give it a whirl. Pick the research task on your desk before your next committee meeting and hand it to super analyst. Start a free trial at alpha-sense.com/capital and see what it has ready for you. Capital allocators is also brought to you by Ridgeline. What would your investment firm do if demand surged tomorrow? Could you confidently say yes to growth, or would the operational complexity hold you back? With Ridgeline's AI Native Investment Management platform, firms are taking on new opportunities with the team they already have in place. Ridgeline brings the front-middle and back office together with all your data in one system. One of Ridgeline's customers now manages four times as many client accounts without adding a single team member. They've also reduced the time spent on reconciliation by 5%, bringing up 10 hours of manual work every week. Ridgeline is giving firms real-time back. What you do with it can change your firm's trajectory. They help firms rethink what's possible, and now they're bringing that forward-looking perspective with their 2027th state of investment management technology survey, exploring how firms are adopting AI, investing in tech, and preparing for the future. Add your voice by taking the three-minute anonymous survey. And as a thank you, you'll get the findings before they're published to see how your peers are thinking about the future. Share your perspective now at Ridgeline.ai/survey. Capital allocators is also brought to you by Juniper Square, the operations partner trusted by the leading private market GPs. One theme that keeps coming up on the show is GPs that build the strongest and most durable relationships with LPs are the ones that have both strong returns and strong operations. AI raises the stakes on operations, and having Juniper Square as your operations partner helps ensure your data is organized, accurate, and accessible so you can unlock operational alpha. That's why thousands of GPs trust Juniper Square. Learn more at JuniperSquared.com/CapitalAllicators. Hello, I'm Ted Sides, and this is Capital Allicators. This show is an open exploration of the people and process behind capital allocation. Through conversations with leaders in the money game, we learn how these holders of the keys to the kingdom allocate their time and their capital. You can join our mailing list and access premium content at capitalallicators.com. Mark Andreessen from 8016-Z famously proclaimed a decade ago that software is eating the world. His prophecy has proved prescient. Cloud computing enabled the rapid cost-effective deployment of software, startups flourished, and venture capital returns have been phenomenal. Venture Capital is a fascinating investment area whose many days in the sun shine brightest this year. Institutional portfolios with large venture allocations soared to their best year in history. And yet, parts of venture are unique in being both efficient and unactionable. Many believe that Sequoia or Benchmark will produce returns at the top of the pack, but there's not much action anyone can take to participate. This mini-series explores the industry, focusing on some favorites of institutional investors who are still investable to those in the loop. Each has a great differentiated story to share and something to prove. That said, this field moves quickly, so as the disclaimer goes, past accessibility is not a guarantee of future capacity. My guest on the ninth episode of Venture is eating the investment world is Annie Lamont, a co-founder and managing partner of Oak HCFT, a $3 billion venture capital firm investing across stages in tech-enabled companies in healthcare and financial services. Annie is a legend in the industry. Across her 40 years in venture capital, she's been featured on the Forbes Myvis list, the top 100 venture capitalist rankings, and received the Healthcare Private Equity Association's Lifetime Achievement Award. Our conversation covers Annie's beginnings in venture capital, inflection points in the industry, lessons learned, and spinning out to start her own firm. We then turned to her investment process, evaluating CEOs, competitive environment, and opportunities in healthcare and fintech. We close with her perspective on women in the industry and her unique experience as the first lady of the state of Connecticut. Venture is eating the investment world is brought to you by Omni. Omni helps private capital investors track and analyze individual deals while providing comprehensive financial and legal insights across their portfolio. It houses the largest database of investment transactions in the private markets extracted directly from executed agreements, including the legal terms, co-investor details, liquidity preferences, valuations, and round sizes. With that information, investors can make faster investment decisions, benchmark deal terms, understand market trends, and enhance portfolio analytics. Omni's clients include leading venture funds, corporate venture groups, family offices, and endowments, including a number of past guests on the show. You can learn more at omni.fund. That's a-u-m-n-i.fund. Please enjoy my conversation with Ann Eaglemont in the ninth episode of Venture is eating the investment world. Any great to see you. Great to see you, Ted. After four decades in this business, take me back to how you first got started. Well, it's-it's an easy story, so I got out of Stanford at the time that Silicon Valley was exploding. It was really the beginning of the whole tech era, and a friend introduced me to this job at a venture capital investment bank boutique that happened to be the leading one, Hemberton Quest in San Francisco. Those were the days when you just interviewed and somebody gave you an offer that after you started the next day. The first three months I was there, we took Genentech public, we took Apple public, I carried Steve Jobs, bags on the Apple IPO road show, and I was just exposed to the two of the most amazing entrepreneurs ever, and I fell in love. I just thought this is what I want to do. I want to be around these creative people that are about transforming the world, and that became my life's mission. How did that take you from that into venture capital so early on? Well, a year and a half into having a job at H&Q. I just said to everybody that I knew, I want to be a venture capitalist, and there weren't many of them out there. Nobody was hiring associates then, or young 24-year-olds at that point, but luckily, a sliding Doris story, where I walked into an elevator, ran into an old friend from Stanford that was working at NEA, went out for a glass of wine, told him what I wanted to be of EC, and the next day he happened to call the founder of Oak about a Victoria Secrets magazine that he wanted him to fund with him. Of course, the founder of Oak said, "We only do tech. We're not interested in magazines, but I'm looking for research associates." Three weeks later, I moved to Westport, Connecticut from San Francisco. What was a venture capital industry like in the 80s? Collaborative, friendly, small. It was not only small, though, in terms of ECs, it was small in terms of opportunities. There just weren't that many companies and great entrepreneurs at that point. I knew, I think, in 1983, there were 300 distrived companies that were all trying to get funded. We had funded C-Gate and fund-1, investment partners, and I had one of the great companies, but I wasn't that interested in investing in distrived companies, and there was only one public software company at that point. It's one of the reasons I actually identified health care and life sciences and biotech is an area that I wanted to specialize in and lead for Oak, and that really established and launched my career. So, what was that spark? work that got you into it. You kind of know what gets you excited in the morning and I did like software but there weren't them any great opportunities to look at and to invest in and the biotech industry was beginning to take off. The year I joined Oak, we founded Genzyme, so I had exposure to that and it just I realized I got really excited about the science and what it could do and it's transformative nature. How did you see even back then being on the east coast when West Coast Silicon Valley was just getting going? I certainly saw more of a plane than any of my West Coast brethren. So traveled a lot but there was Boston, was an active community, Genzyme was obviously in Cambridge and I certainly had to travel more but I actually loved being outside of Silicon Valley because I think it over my career is made us think differently. We aren't stuck in group think and have been invested all over the country and now globally. What was an early investment that you just always remember sticks in your mind? Sure, well they're all mentioned too because one was the success and one was the failure. So soft switch, I did it being bought by Lotus 1, 2, 3 and then by IBM and that actually was the first days of intra email, essentially it was corporate email and so that was a fun one because that was all the way back to 83 in terms of anything about that was really the days before ubiquitous internet email and then the other one was actually a competitor market vision to Bloomberg. So I wish I'd been in Bloomberg but instead we were in market vision which didn't make it. What was the story of market vision? Well I think it was an entrepreneur that became obsessed with hardware and the graphics and not the software and the business model and Bloomberg was so brilliant around the business model and obviously the software at that age. How did you learn how to be good at this? Well it isn't a apprentice business. You do learn from the people you know I was working with people who've been in the business for over a decade at that point and there weren't that many people. The pace was slower so you had time to actually study things. I think the most valuable advice I got was from Jerry Gallagher who was our retail partner and been involved with many of the greats Whole Foods and Petsmart and Office Depot and had been involved with many great stories and he said to me about five years into my career I don't think that you're focusing enough on the quality of the CEO and I was more focused on the maybe the idea and the market opportunity and I think he was absolutely right and it seems so simple but for me it's always all about people and I think developing and the reality is I think it's all about judging the people on the person leading the effort. What does that mean on the margin? Not focusing enough on the CEO and what did that mean to you at the time? It meant that CEO comes first. Everything is about that CEO and don't ever compromise, don't get excited. Even with financials that may look good, if it's far enough long to have them just be looking at the individual start with the ethics and go to just the quality of the team obviously that they can attract. I mean you have to be a pied piper to really be a great entrepreneur, a great leader. People have to want to come work for you and you have to be secure enough so that you want people that are even better than you and smarter than you to work for you. Somehow we got to jump from then to today and maybe the way to do that is to ask about what were the inflection points? So you started in the 80s, it was quiet, there weren't that many people. Totally different story today. If you look back, how do you map out what those couple decades have been like? The Internet Mania, period 98, 99, 2000, that was an education itself. Beginning of the Internet, beginning of e-commerce, fascinating period. If we hadn't had a Mania, we wouldn't have funded things like Google and Amazon, some of the great companies of today. But you also learned what business models worked and what didn't and I feel like we're hitting a second Mania of the last couple of years but with many more great entrepreneurs and business models and companies. So at that time what I learned was in 2000, 2001 when there was a retrenchment, when we felt like the opportunity set wasn't there. It made me think more about the different sectors that I was in, what I would be doing. Frankly, I had vectored away from life sciences because you could see by 99, 2000 that there were 3,000 public biotech companies and only five approved products. You could see that the science wasn't there yet and that it wasn't, people just assumed that because you were working with molecular biology, that these products would work better that the trials would go faster than those with chemistry and it just wasn't true. So there ended up being like a 10 year drive period between 2000 and 2010 and there were very few great biotech companies created, taken public. So I actually stepped away in 99, 2000 from life sciences and made it a mission, frankly the crash gave us time to rethink, repot and I did two things. One became about cloud, became about cloud and didn't software on our mission became about lowering cost in healthcare, improving quality, improving the consumer experience and that became our mantra. So within healthcare. Within healthcare, all software and services, so within health was our first, we led that deal with largest investor in 2000 but I also started a fintech practice because I keep yourself fresh intellectual curiosity. If you looked at business models that were working areas that people weren't yet, just like when I was early in biotech, I just felt like nobody was doing fintech. People didn't even know what I had to tell people what the word meant. Very few companies in the sector but incredible business models, if you think about payments, what's happened in the conversion of BTC payments and now B2B payments and so we really mostly focused on payments at that time and as we established fintech practice in 2002. So sometimes these meetings and then the breakage ends up giving you time to rethink and vector into different directions. So it's interesting because a lot of people then think about 2008 as the next point and the reality is 2008 was problematic for public markets. It was problematic because people had to retrench in terms of how much they could invest and down its were decimated, people didn't have as much money to invest but it actually reset valuations and in the micro markets that we were investing in, they didn't affect the opportunity there at all. It was already fintech, the decision of healthcare, all those things were already beginning and so it didn't change our opportunity set, put a reset so we could actually invest in great valuations. So it was actually a wonderful time period and the last 20 years have been an incredible time period to invest in the two sectors that we're in. So I'm curious in that you spend 20 years basically just focused on healthcare and with such a CEO person focused approach, how did it feel to reset almost like your network? I think you have to be humble, right? It takes some humility and I think a lot of people don't want to do that, they're king of life sciences or they're king of a particular sector they're in and the reality is if you're excited about learning, you want to learn something new, creating fintech, creating a technical solutions and services area and healthcare, it just meant you were meeting a lot new people, you were asking a lot of questions, you weren't the smartest person in the room and you have to be willing to do that. I think that is the core of being a successful investor. As you come out of the crisis a couple of years later, you decide to spin out, walk me through that whole thought process. One thing that happened and I have to give Andreessen some credit for them, their model in terms of 2007, 2008, about the same time as the crash was interesting, and more money came into the industry, we became more of a service industry and I was living in a partnership where fintech and healthcare was doing very well, tech was struggling more and people didn't want to change, culturally, they didn't want to change to a service model, they didn't want to invest in the platform and we could just see that the fintech and healthcare team, Andrew Adams and Tricia Kemp and myself, this is only the beginning of healthcare and fintech, this is going to be an incredible runway, the tail ones were amazing and we wanted to invest in a platform that focused on a talent function like we have now with five people on it and we're going to be adding more with an incredible leader there. We wanted to bring in operators that were dedicated and focus these two areas of healthcare and fintech and have them be part of our team and really just everything that we could do, the best of both of these sectors and no deep as investors and operators, we wanted to build, so it was a really exciting time and it still feels like a startup, we absolutely love it. So in that transition which I guess is now seven, eight years ago, you don't often see both a spin out of that ilk but then also a retention or at least a rolling over commonality of the brand to some extent, right from oak to oak, HCFD, how did that play out? I think we felt that we were oak, you know, people knew us as that, we think it was for a long time as that we could have certainly many new brands have come into play, many people rebranded that it was spun out, but the existing entity, oak investment partners wasn't going to exist any longer. That entity we all agreed was going to die, we were going to roll off all the companies and we were the surviving new entity, essentially HCFD, so you could call us oak, but the healthcare and fintech team, they actually spun out started a new entity and we weren't going to name ourselves oak and balsam partners because it was no longer oak and balsam partners. So I'd love to dive a little bit into the opportunity. opportunity sets of each of the sectors. So you mentioned in at least life sciences, you had this very foul period until 2010. Not many products, but lots and lots of public companies. What's played out since? - Well, in the life sciences side, we do technology enable solutions to pharma, employers, payers, providers, consumer. So those are all markets and customers that are companies that will address in terms of directly investing in the biotic and life sciences companies that take FDA risk. We won't do that. Now, certainly as of 2010, I would say 12, the life sciences industry came to life again. There've been an extraordinary, you know, Chris Burramy, you can just list the number of innovations that have occurred that have made it incredibly exciting again. But we really felt like we were on this mission and there was incredible amount of opportunity to improve the system. And the healthcare system was so broken that that was really our mission. Not to be a life science investor. And we don't really love binary outcomes. And that's really what you have as a life science and it's either great or it's not. It doesn't work. - And how about FinTech? - FinTech, it's so broadly defined. I mean, it starts with payments because to ensure it's a good, be prop tech, e-commerce enablement. FinTech and payments is really embedded in every industry. And it's one of the reasons there was incredible conversions between healthcare and FinTech. Two highly regulated industries, but a third of what we do is the overlap between these two sectors. There's sometimes we call healthcare, but they're really payments companies and healthcare. - I'd love to walk through effectively your investment process. How do you think about the top of the funnel? - Well, we have these strategic themes. The top of it, we have incredible networks. We don't call, we're in a, like a TA or an insight, have a bank of kids that are trying to find deals, it's not the way it works, we may call people because we've identified a strategic area and a few companies specifically in that area. But 90% of what we had is not books. We don't generally invest in companies that have come from the lesson bankers, but it's just proprietary deal flow. We've lived in these two sectors so long. Our network is just fast and deep and we have great relationships. And this is such a relationship business that it just comes from that network. - How do you balance today that same vector of the CEO being the key part of your investment thesis compared to all these interesting things and the trends in the industries? - Well, CEO is number one. There are CEO's that we backed 15 years ago. We would never back now. And CEO's who had positive outcomes, but it's that much harder now. It's that much more competitive. The companies are growing that much faster. So CEO's just have to be better and there's more demand of them. Which is one of the reasons we created this talent function because the first thing we do is make sure that that individual is surrounded by the best team possible. And CEO's are growing out of teams every two years. So we're placing half their management team because they can't scale fast enough with the companies. It's a different world we're living in. Then we were a decade ago, 15 years ago. It's just more as expected of everyone. The reason we do early end growth, I think it's really important to think about it. 10 years, 15 years ago, a growth company was very unlikely to be dislocated by a new company, or a five-year-old company being dislocated by a new company, probably not happening. Now, it happens all the time. So we really need to know what is going on with new seed stage companies in order to be the best growth investor. And some of our strategies in growth are organic and inorganic growth. So you're going to see that more and more. I mean, with these big fundraisers, people are consolidating industries and with the public markets declining and more challenges probably in the private market in terms of raising money. You're going to see companies that are really products and not platforms be sold and be incorporated into these platform companies that we hope to be backing. - I'm curious what you've learned about characteristics of the most successful entrepreneurs you've worked with. - Well, I would say confident, but not arrogant. - So, supremely confident, because you need to be confident to ask questions. You need to be confident to hire better people than yourself. So I think that that's really important, but you also need a massive intellectual curiosity and confident enough to ask anyone and everybody questions, but then be a decider, right? You need to be incisive. Like, take the data, make the decision. Like, you're the decision maker. It rests on you. I can give you all the advice in the world, but it's up to you, you're living with that decision at the end of the day. You have to be a Pied Piper. People have to be willing to follow. They have to get excited. I have to work with a person. This has to be fun. We're involved with a lot of companies. It's a job, it's really not just a job. This is when we live and breathe every day. And I think that if you're not join working with somebody, then other people aren't going to enjoy working with this person, right? They're not going to be able to attract money. They're not going to be able to attract talent. That wears thin after a while. So, all those go into the soup. How does your intelligence process work? Which depends. If it's early, there's not much to look at. It's really just a judgement on people. But other than understanding the market and understanding what the competition will look like and how you fit in because the world's getting more complicated, with so many companies being funded in similar areas, you do really need to triangulate and understand what that looks like better than you used to. And then otherwise, we don't hire McKinsey. We don't hire Bane. We never hire a consultant. We know these companies. We know what they do. We don't need to be told. I mean, we live it every day. So, that kind of market research is so easy for us to do and customer research. And we know the buyers of these companies. We know the person in the particular department within United or Anthem to call them and just have a friendly off the record conversation. So, I just think it's just so much easier to actually do due diligence things. And then obviously, we've got all the financial and modeling we need. - So, once you go into a company, you've got your talent team. You've got operating partners. How have you figured out you can best leverage the talent that you have to help companies? - We review it weekly. We go to market, for example, as one issue, when we had a couple of companies, we thought could use some help there and often there are usually companies that need help there, right? And we did hire like Mike Mateo, is somebody who was head of growth at United and was president of what was Grand Rounds. And he's full-time helping three of our companies in a work on that issue. So, it's more of what's the need? What needs do we see by engineering talents? So, we may end up with a function that's completely dedicated to finding a engineering talent for such a crisis. It's just a talent war out there. - We're gonna take a quick break in the action to tell you about Brookfield. Brookfield invests in the thing behind the thing, behind the next big thing. They're focused across infrastructure, energy, real estate, private equity, and credit is helping to build the backbone of the global economy. Brookfield combines deep operational expertise with disciplined long-term investing, uncovering value and partnering alongside clients to shape tomorrow's economy today. Invest in the businesses that shape tomorrow. Learn how you can own what's next at Brookfield.com/own. - This is not an offer to sell or investment advice. Investing involves risk, including the loss of capital. And now, back to the show. - How do you think about the competitive landscape? So, you mentioned you're still doing early stage or also doing growth. You're of real size, not mega size, but certainly not a minnow. - It's all about positioning ourselves as this great assist and support system for great entrepreneurs. And that's whether you're starting out or whether you're pre-public. So, it really hasn't been an issue because we feel like the financing side of it is like a commodity. We can model, we've done pipes, we've done every kind of transaction. That's the easy part. The harder part is identifying the right company in the right sector and then helping that entrepreneur be the best that they can be. So, it's easy positioning because it's really first about the domain and your expertise and your relationships, you understand how much you can help somebody. And I think I've been involved with maybe 75 exits of companies through every means, strategic to financials, to IPOs, to SPACS. So, we can also be incredibly helpful there. - I'm kind of curious with all this money sloshing around. How has that affected the deal environment, even with the relationships that you have in these sectors? - I think it's just moved price up. It's not that we're losing deals. It's just, what are you willing to pay? Early is all more expensive, but it's not that we care if we paid 60 million or 90 million, it's in the grand scheme of things. Is this company worth, could this be 500 million or a billion or two billion or three billion? So, we don't get hung up on the early stages in terms of valuation. And so, I think we've probably moved a little earlier from growth and earlier, and we've done a little bit more early stage. And we work with a lot of repeat entrepreneurs, so that mitigates losses. And I don't worry about that. But I do think we're in a reset mode right now. Public markets have corrected dramatically. They already had in healthcare before the end of the year. And now in Fintech, you know, we've seen that in the last couple of weeks, pretty dramatic reset to the point of, it's almost ridiculous. There's some public companies we want to buy right now. So, I do think the pace will slow, but these environments, there is a lot of money still out there. They'll be a separation of wheat and chaff. And those that are truly exceptional companies, we just invested in a company, Paxos, a couple months ago, $2 billion valuation. We're already getting offers and more than twice that for that company. So for great companies, people still want to invest, people still want to buy them. That isn't going to change. I just think the filter is going to be much higher, and there will be compression and more realism. What could we actually sell this for? What could we get liquidity on this for in a public offering, or could it even be a public company at any point? So that's going to change. What are the themes you're most excited about today? In healthcare, it's really a pay-vider model, is one of the things we're very, very interested in, in probably because it has the most impact on cost reduction and improvement of quality of care. A pay-vider could be a devoted, that's a Medicare Advantage plan, that's incorporating a provider model, so that they have their own devoted medical group, virtual primary care effectively for their own participants, members, and the Medicare Advantage plan. It's the merging of that where you're actually managing the care and taking the risk on the care, or it could be a Village MD, that comes at it from the inverse, where Village MD is a primary care provider that's taking global cap risk, is taking risk on those patients and with an MA plan, Medicare Advantage plan, and saying, "I will manage the merge in these people. I will day-to-day be responsible for these people's care, and I will provide all the infrastructure and data around doing that well." It's worked incredibly well. The numbers in terms of increased star ratings for MA plans that work with them, the quality of care they're delivering, and the reduction in cost of care is extraordinary. This is truly what should happen across America at every level, it's like you really should have doctors at risk for managing patients over the long term. That's what's going to have the most impact. The other thing, if you just think about the staffing challenges, think about automation in healthcare, we found that whether it be a payer or provider's hospital systems, they really didn't care three years ago about efficiency automation. They cared about revenue enhancement, but they really didn't care about efficiency, and they threw staff and bodies at everything. Three years later, staffing is a massive challenge for everyone. The cost of labor is going up dramatically, so they're very focused on automation. We've come as olive and syllable and notable that where their products, the acceleration in their sales is impressive because all of a sudden hospital systems pair are like, "Wow, I really need to focus on efficiency. I need to focus on automation," so I think that that is going to be a huge area for us, and I think it's, I've been waiting for this for 20 years, and it's now finally happening. I think that's exciting for the system because before there was a pushback also of, "Oh, they're automating people out of jobs," now it's like even truck drivers. They were worried about truck drivers five years ago. AI is going to eliminate jobs for 8 percent of males in America, and they're like, "No, we don't have enough truck drivers. We need automation." What are the other changes to see in healthcare coming out of COVID or hopefully coming out of COVID? Well, I think the other thing is just the virtualization of care is most important. There was a massive acceleration in virtualization, and everybody realized that you could actually visit with your doctor online. What that does is, if you think about the cost of care so much of it, like a third of the cost of care is in the hospital, and most of the time you don't need or want to be in the hospital, or even a nursing home who wants to be in a nursing home after COVID, right? In the institutional settings, it's the most dangerous place you could be. So, you want to be in your home. Most people want to be in their home. They want to stay in their home, and they want to have the care and support where they can stay in their home. And so, virtualization, I just think you're not even going to recognize it. The automation, robotics, sensors, just the care platforms about managing caregivers that are managing individuals in their home is going to be dramatically different. And so, we are seeing much more investment going into how and care and virtualization. That's just going to be extraordinary. Are there particular angles of types of companies playing into that that you're excited about? They were involved with at some level, but dispatch is actually providing, they have cars that literally provide ER and hospital-based services in your home. They come to your house, and it dramatically lowers the cost of care. It's fascinating. They're rolling out across the country. You've got Vesta and Carebridge, which are monitoring caregivers in the home and helping them and taking risk contracts to manage these caregivers who have been, think about, talking about $12 an hour workers that are responsible for very sick people in the home with literally no support in the past. So, if you bring a model around them, and nobody's to look at the total cost of care with these patients, and now that somebody's responsible for that risk, and you then have a service to manage those people in the home and you keep them out of the hospital and you keep them more well, it's a winning financial model. I was curious if you flip over to the FinTech side. You mentioned Paxos, which of course leads into the whole crypto world. How are you thinking about crypto as it relates to DeFi and FinTech? I think the COVID was as impactful for FinTech as it was for health care. Certainly all these services that one would go to a bank for, would get title insurance, would show up at a lawyer's office, all those things were digitized, all of a sudden payments and services and mortgages were digitized and you were doing it from your back. And so, companies that we were invested are doubled in sales during that period. It was just fascinating and obviously the pandemic has been incredibly negative event for so many education, mental health. But in terms of making progress in the use of tech for health care and FinTech, it's been extraordinary and moved us five to ten years faster than we would have. So from that perspective there will be lots of great opportunities to come out of that. On the crypto side, we haven't been investing in it as a currency. We haven't been investing in crypto per se, but we invested digital asset infrastructure. So Paxos is digital asset infrastructure. It's what we do. We've been doing B2B enterprise software in effect. And if you think about digital asset infrastructure, that is basically just taking blockchain and applying it to different use cases and we've been waiting for that for seven years. But now those use cases are here and we're seeing more and more companies where this digital asset infrastructure makes a ton of sense to use the blockchain for different opportunities and use cases. Paxos effectively makes everybody coin base. They've got the fully regulated, white labeled infrastructure, so any entity can be coin base. You step back, I know you've spent plenty of time at the industry level in the National Budget Capital Association. And as a long-standing woman in an industry that we've seen over the last couple of years has not had a sort of proportional share of women in the industry, I'd just love to hear your perspective on that issue and your history with it. Yeah, I would say a couple of things. After the first year or two, and I think they probably thought I was the founder's secretary, the first year walking around with them, I don't know. There were so few women in the industry, but I was made a partner very early. I had agency. I never felt, in fact, I almost felt it was like a great filter because if an entrepreneur wanted to work with a woman, it was like a value system test. I never really thought about that way until later on, but I just had these really wonderful entrepreneurs I worked with and I really never felt, I don't know, I just didn't feel discriminated against by entrepreneurs, by other VCs. I loved everybody I worked with and I loved the industry and I was always wondering why there weren't more women in the industry, but I would say 30 years in, I was like, wow, there's some fundamental structural problem here that hasn't brought women into the industry. And I do think not enough mentors and people didn't see it as a room. And guys were getting into college and already talking about PE or VC and talking to their guy friends and talking to their friend who got out of school and what was the avenue and women weren't doing that 10 years ago. And I do think that, I think there are two things. Call it the Me Too movement, but I also think it's the generation of, like, this group of millennial women are empowered, are CEOs, are VCs, you know, there's just a difference in the nature of their empowerment. And I do think that it happens simultaneously. You're going to see more female CEOs at the same time you're seeing more VC and VCs. And it's happening. We're still a fraction of the industry, but it's not like a just a token female here and there. They're coming into the industry and we've had much better luck in the last five years, hiring women who are looking for these jobs and we're seeking them out. We definitely had to go past the traditional channels, but they're seeking us out now. So it's very different and I don't have to educate people and women on the industry. They understand it and know about it and the next 30 years is going to be very different. I'm super excited about it. I'm kind of curious as you look out in what's obviously been a super hot area, it's just sort of the industry in general, where do you see the structure of the industry playing out and kind of. competitive differentiation of different types of firms. The industry is changing more now in the last two or three years, and I think I've ever seen it. I think that's because one, particularly when you get into tech and fintech, it's global too, because some very large funds have been created and brand matters. And this is a generation where brand is really important. So I think that you have to have scale. It's very hard to succeed. And even I think seed funds are having trouble, because firms that can do seed, start up, series A, B, C, and promise to be there with the entrepreneur all the way along, have an advantage against an even a early stage seed fund. Don't get me wrong. They'll be great, wonderful seed funds. They'll still do amazing work and be relevant. And it's one of the reasons we're getting bigger, because we just feel like you have to have brand and you have to have market share. I mean, we were last year, we were 30% of the rounds that were done over 100 million in our sectors were OKGFT companies, and that is a pretty powerful stat, and those were all over a billion dollar rounds in terms of valuation, and we want to have market share. If you don't have market share, it's hard to have impact. And the market share is like this network effect of being in these companies, and that introduces you to other companies, and those entrepreneurs recommend you to other entrepreneurs, and the VCs, it's just this network effect is real. You have to maintain quality control. We don't want to be the index fund. I could name a few. They've got that approach going, but so we don't want that. And we'll stay focused on healthcare and FinTech, and we'll just be the best in those two sectors. That's our goal. So scale matters, but you don't want to be too big. And then there's always, as in size, the enemy of performance. You don't want to be too small. When it really comes down to brass tax, how did you decide how big to get, and what felt right? I think we have kept every fund is about 20 to 25 companies. So that's been an important stat. We've gone from three people to 40, and the last eight, seven and a half years. We've been very, very careful. We have one person dedicated to hiring four oak within the team in terms of filtering. And every person that we hire, we have to believe could ultimately be a partner that they may not all make it, but it just very high bar and every person that walks in the door. So I think that as long as we're not creating 100 companies in a fund, and we're just spraying money out there, and the bar is very high on each company that we're investing in. We're going to feel very good about our returns and the quality of what we're doing. How have you thought through the math of, you still want to be 20, 25 companies? Fund sizes get bigger so you can scale. There's a math equation. Like, how did you solve that puzzle? Well, I think the industry solved it for us because the size of a series B and C is three times what it was five years ago. So we have to be bigger in order to and get a lot size or be able to lead around that became just a fact. Now, if you think about our prior life, we were investing out of multi-billion dollar phones. So we had the ability to write 50 to 100 million dollar checks. So we're really just back to our roots in terms of that we are doing seed and early, but we're also able to write the larger checks. Now, you've been through a few cycles in the past and last year was great. We know there's some stuff selling off right now. How do you play the game at a time that feels like until very recently, at least, things have been really, really good? Well, I'll give you an example from our fund three and fund four. So fund four was invested in 2021. Fund three was the year before. Fund three, we could feel the momentum acceleration in companies growth as well as valuations. So we actually moved very quickly to invest in companies and we ended up with an extraordinary number of companies that raised money at much higher prices very shortly after we invested. Now, fund four in 2021, we became more concerned about the valuation environment. So we certainly did some billion dollar plus valuations in great companies like Paxos, but we also got more value-oriented. So we are not just momentum players. We are theme and trends and we started more companies with repeat entrepreneurs and some new great entrepreneurs and we dealt with the valuation issue and we did, I would say, more growth that would be build-ups. You buy into a platform and then you can see the writing on the wall that you're going to be able to then buy companies that aren't going to get funded, that are products. And so we have more organic and organic companies, I would say, in that portfolio. So we absolutely adjust what we're doing and get creative every cycle every year. What do you must worry about? I suppose we worry about the little things all the time, but these two sectors have incredible opportunity. I feel like we're positioned very well. I just think you're always, it's such a competitive world that you're just always saying like we had brought into Latin advisors. We've now made two investments in Mexico. We're always like of re-evaluating when we should do things. So I worry, it's just keeping your eye out and really never settling and never thinking you've got it. You're always learning and you have to just continue to reinvent and it's partly reasons like using bigger funds and expanding because you need the resources to do that, to bring great operators on, to have venture partners, to have relationships, to have advisors in Latin America, to have a presence there, to have potentially a presence in Europe. We're like the leading FinTech growth investor in Israel. This takes capabilities. It's exciting. It's opportunities. That just keeps you energized about what you're doing. How much of that feels like it becomes an arms race because yes, you want to have people in all these different geographies and you want to have people, but at the other extreme, that's what's created all of the growth and assets. We will be small enough so that the managing partners and partners here will have a lot of touch points with all of these companies. And we're getting liquidity to fairly rapid rates so that we won't have too many companies are portfolio. I think honestly, Andrewson, General Callis, I'm done great. You get as many people and as much money as they have, there's no way the senior people are involved with every company and we are and that will remain. I have a couple of closing questions I want to ask you, but before that, since we're both living Connecticut and we're sitting in Connecticut, I have to ask you have taken on by, I guess, election this role of quote unquote the first lady of Connecticut. And we'd love to hear what your experience has been. It's certainly a fascinating inside window into government and I think what's fascinating, what's wonderful to me is that I think citizens now appreciate the importance of good government and the role governors play. There's a very direct correlation between what a governor does that affects your life and certainly think that my husband has great common sense and has been able to blend these different capabilities. So I think that's been interesting and I do think like the perspective on Medicaid and Medicare and I'm a political science major from Stanford. So I'm actually interested in public policy and it's one of the reasons that I get into health care and it's one of the reasons that I get involved with Fintech. I mean, these are highly regulated industries where public policy matters a lot and it matters in terms of how it impacts its citizenry. Have you had the opportunity to sort of do anything in that seat at a state level? There is no prescribed role. I think it's just being supportive of my husband and obviously he's become a health care expert the last two years and he never wanted, he couldn't spell health care before that. So not something he loved talking about but now he loves talking about it. So we've got a lot in common and I think that's been good. And one thing we have done is created a a seed angel capability, a tax credit for it. Connecticut Innovations is amazing vehicle for investing in real estate companies. We've been an advocate. I've certainly helped him introduce him to entrepreneurs in terms of fostering the seed in an entrepreneurial community ecosystem in Connecticut. That's something that's been fun and positive hopefully and hopefully people perceive it that way. It's more of just I think it's important and we've created a female-oriented seed group, a little title river, and gotten amazingly in three years. It's gotten organized and it has its own team that's now running it and it's gotten women and going to get involved. So it's great. Fantastic. All right, Annie, before I let's go, a couple of closing questions for you. What is your favorite hobby or activity outside of work and family? It's being outside in any form of activity. Hiking, biking, tennis, golf, skiing as long as I can be outside doing something athletic. I love that. What's your most important daily habit? Getting up in exercise. I think you used to be running every day. I do a little less of that and yoga and every day it's a different spinning, Love, Soul, Psycho, Miss Soul, Psycho. cycle inside and having a green drink. - What's your biggest pet peeve? - I don't love people talking on cell phones, loudly and trains are closed spaces. I'll choose that. - Have that on the investment side, you're biggest investment pet peeve. - I think it's bad people winning. I'm a social justice person, sort of righteous. And maybe a little too righteous on that front, but I just, you know, they're entrepreneurs that are not completely ethical who win and they're certainly, you know, VCs who I don't respect. You know, so I think it's just, I like good people to win. - Which two people have had the biggest impact on your professional life? - Well, I'd probably say the individual that introduced to me to Oak in the first place. Probably I have to credit him. I mentioned Jerry Gallagher. He was a partner in retail who was very midwestern like me and reinforced the golden rule and it's all about people and all-fashioned relationship. It's just what it's about at the end of the day because this is a job that is, we've worked with entrepreneurs three, four or five times and it's been fun and it's been rewarding. So I think he's had a huge impact and then I have two incredible partners right now in Andrew Adams and Trisha Camp. And it's a joy every day to work with them and it's just all about intellectual honesty and having fun and building a great team. - What's the biggest mistake you've made and what did you learn from it? - Not starting my own firm center, absolutely. Change is hard and you've done something for a long time. I think it's hard and that absolutely should have done center. - What teaching from your parents has most stayed with you? - I'd go back to the golden rule probably and kindness. I think they were very lovely kind people and highly, highly ethical. Just treat people like you'd like to be treated. - All right, great. Any last one, what life lesson have you learned that you wish you knew a lot earlier in life? - Hmm, don't sweat the smallest off. You won't even remember it later on. You know, there are only like a few pivotal things. We know obviously your kids are the most important thing. So and everything seems important when they're younger. But I do think in the end their pivotal decisions you make and otherwise most things will work out in the wash. - Annie, thanks so much for taking time. - Absolutely great to talk to you Ted. Appreciate it. - Thanks for listening to the show. If you like what you heard, hop on our website at capitaliselcators.com where you can access past shows, join our mailing list, and sign up for premium content. Have a good one and see you next time. (upbeat music)

Podcast Summary

Key Points:

  1. AlphaSense’s "Super Analyst" AI tool automates research by analyzing 500 million premium sources, learning investment themes, and generating briefs, models, and memos with full source traceability.
  2. Ridgeline’s AI-native platform integrates front- and back-office functions, enabling firms to manage four times more client accounts without adding staff and reduce reconciliation time by 10 hours weekly.
  3. Juniper Square supports private market GPs by organizing data, ensuring accuracy, and enabling operational alpha through trusted operations partnerships.
  4. Annie Lamont, co-founder of Oak HCFT, began in venture capital in the 1980s, pivoting from biotech to healthcare and fintech after the 2000 crash due to poor market outcomes.
  5. Her investment process prioritizes CEO quality, team dynamics, and operational talent, with deep sector expertise and relationships driving deal discovery.
  6. She emphasizes that successful entrepreneurs are confident, intellectually curious, and capable of building teams better than themselves.
  7. Healthcare and fintech are now key sectors, with strong focus on pay-viders, automation, virtual care, and digital asset infrastructure like Paxos.
  8. She highlights gender inclusivity in VC as a structural issue, noting increased female participation due to millennial empowerment and targeted outreach.

Summary:

Annie Lamont, co-founder of Oak HCFT, shares her 40-year journey in venture capital, starting in the early 1980s with a focus on biotech before pivoting to healthcare and fintech post-2000 market crash. She emphasizes that the most critical factor in her investment decisions is the quality of the CEO—someone who is confident, intellectually curious, and capable of building superior teams. Her process combines deep industry relationships, rigorous due diligence, and a focus on operational excellence, including dedicated talent teams to support portfolio companies.

She highlights transformative trends in healthcare, such as pay-viders and home-based virtual care, and fintech innovations like blockchain infrastructure via Paxos. Lamont also reflects on the evolving VC landscape, noting increased competition, the importance of brand and market share, and the need for disciplined fund sizing. She attributes success to a strong network effect and ongoing learning, while advocating for greater gender inclusion in the industry.

Her experience as Connecticut’s first lady further underscores her commitment to public policy and entrepreneurial ecosystems. The episode positions venture capital as a dynamic, people-driven field shaped by innovation, adaptability, and long-term vision. Platforms like AlphaSense, Ridgeline, and Juniper Square are highlighted as tools that support capital allocators in research, operations, and data management.

FAQs

Super Analyst is an AI-powered tool that continuously monitors over 500 million premium sources like earnings calls and research reports. It learns a user’s coverage universe and automatically generates briefs, models, and memos, saving time and ensuring insights are aligned with the user’s preferred templates and projects.

Ridgeline unifies front, middle, and back-office functions into one system, enabling firms to manage more client accounts without adding staff. One customer now manages four times as many accounts and has reduced weekly manual reconciliation time by 10 hours.

Juniper Square is an operations partner trusted by leading private market GPs. It ensures data is organized, accurate, and accessible, enabling GPs to unlock operational alpha and build stronger, more durable relationships with limited partners.

Annie Lamont focuses on pay-vider models in healthcare—where providers manage care and take risk—to reduce costs and improve quality—and in fintech, on payments and B2B transaction technologies, especially in highly regulated industries like healthcare.

The CEO is central to her investment thesis. She emphasizes that a strong, ethical, and confident leader who can attract top talent and inspire teams is more critical than financials or market opportunity alone.

She notes a significant shift post-2000, where the biotech sector faced a crash due to poor science-to-product translation, leading to a reevaluation. This prompted a pivot into cloud, healthcare software, and fintech, which became her core focus areas.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.